Apellis Pharmaceuticals Inc APLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APLS is a good fit for your portfolio.
News
-
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
-
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
-
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
-
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
-
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
-
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
-
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
-
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
Trading Information
- Previous Close Price
- $35.41
- Day Range
- $35.10–36.59
- 52-Week Range
- $19.83–87.77
- Bid/Ask
- $35.42 / $36.25
- Market Cap
- $4.40 Bil
- Volume/Avg
- 1.2 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 702
- Website
- https://www.apellis.com
Comparables
Valuation
|
Metric
|
APLS
|
ABOS
|
ITOS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 16.48 | 0.53 | 0.93 |
Price/Sales | 8.36 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
APLS
ABOS
ITOS
Financial Strength
|
Metric
|
APLS
|
ABOS
|
ITOS
|
|---|---|---|---|
Quick Ratio | 2.78 | 29.83 | 12.80 |
Current Ratio | 3.77 | 30.20 | 13.51 |
Interest Coverage | −13.74 | — | — |
Quick Ratio
APLS
ABOS
ITOS
Profitability
|
Metric
|
APLS
|
ABOS
|
ITOS
|
|---|---|---|---|
Return on Assets (Normalized) | −38.34% | −19.28% | −16.56% |
Return on Equity (Normalized) | −114.50% | −21.04% | −18.86% |
Return on Invested Capital (Normalized) | −81.23% | −24.75% | −22.78% |
Return on Assets
APLS
ABOS
ITOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ktfljpbt | Dpjh | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vxzrdppf | Nxshw | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jqvxcfxn | Wpqhv | $114.0 Bil | |||
| Moderna Inc
MRNA
| Bsdfrjbh | Wjhk | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xfxrxrny | Tmzqvj | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Jffpxngs | Zsrs | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Jnmjzjjx | Cqcr | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bmntjnl | Zfmwqm | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Lrvqbppq | Cssj | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Hmtqdsjt | Lzlnbs | $11.6 Bil |